Friday 6 November 2026 Export RCUS’s income statement to Excel — free account

Arcus Biosciences, Inc.

Arcus Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $247.0 million, down 4.26% from fiscal 2024.

Revenue: −65.4%
EPS: +21.3%
Free cash flow: +9.28%
Total debt: +4.08%

Quarter to September 2026, against a year earlier

18.39 0.70 +3.96%

Follow RCUS

Alert me

Market cap: $2.5B
P/E: 0.0×
Fwd P/E: −5.1×
Dividend yield: —
F-score: 0/9
Altman Z: 1.11
Beneish M: −2.42
Dividend safety: n/a

Overview

Arcus Biosciences, Inc. (RCUS) P/S ratio

Alert me on P/S ratio

As of 5 November 2026, Arcus Biosciences, Inc. (RCUS) trades at a P/S ratio of 22.8×. Over the past ten years it has ranged from 0.0× (June 2018) to 162× (August 2018); the current reading is higher than 62% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.5×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/RCUS/ps-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Arcus Biosciences, Inc. P/S ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/RCUS/metrics/ps-ratio">Arcus Biosciences, Inc. (RCUS) P/S ratio — stockrow.com</a></p>

Period	P/S ratio	Change
FY2025	10.4×	99.26%
FY2024	5.2×	(58.22%)
FY2023	12.4×	(4.15%)
FY2022	13.0×	77.34%
FY2021	7.3×	(59.85%)
FY2020	18.2×	(38.19%)
FY2019	29.5×	(33.89%)
FY2018	44.6×	—
FY2017	0.0×	—

Period	P/S ratio	Change
Sep 2026	32.9×	(0.96%)
Jun 2026	33.2×	189.51%
Mar 2026	11.5×	10.77%
Dec 2025	10.4×	71.69%
33 more quarters	Free account

Against its own ten years

Low 0.0× High 162×

Ten-year median 12.4×

Current reading's percentile 60

Company	P/S ratio
PHVS Pharvaris N.V. compare	n/m
MBX MBX Biosciences, Inc. compare	n/m
ZLAB Zai Lab Limited Unsponsored ADR compare	5.7×
BEAM Beam Therapeutics Inc. compare	18.6×
RCUS Arcus Biosciences, Inc.	22.8×
XNCR Xencor, Inc. compare	24.8×
RXRX Recursion Pharmaceuticals, Inc. compare	27.9×
IDYA IDEAYA Biosciences, Inc. compare	86.7×
NAMS NewAmsterdam Pharma Company N.V. compare	91.1×
Biotechnology industry median	9.2×
Healthcare sector median	3.5×
Market median	1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

Arcus Biosciences, Inc. (RCUS) P/S ratio

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on RCUS

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on RCUS

Stockrow Weekly